Pacira BioSciences, Inc.
No SEC Form 4 filings for $PCRX in the last 30 days.
See all $PCRX insider activity →Pacira BioSciences (PCRX) partnered with Molteni Farmaceutici to expand sales of its pain relief drug EXPAREL in the EU and U.K. The deal includes an upfront payment, supply price, and future royalties for Pacira. Financial details were not disclosed. The agreement aims to increase EXPAREL's market reach.
PharmaCorp Rx Inc. (PCRX) completed two acquisitions: a $1.3M pharmacy and a $475K prescription file purchase, expanding its network to 17 pharmacies. The company also increased its acquisition facility with CIBC from $17.5M to $27.5M. Additionally, it signed a non-binding LOI for three more pharmacies in Atlantic Canada.
Pacira (PCRX) discussed its Q2 2026 earnings call, focusing on EXPAREL commercial momentum and pipeline progress. It said it secured UnitedHealthcare coverage for separate reimbursement, reaching 150 million covered lives by midyear toward a 160 million goal. Pacira also reported iovera divestiture completion to Zimmer Biomet on July 31 and outlined Phase 2 PCRX-201 Part B enrollment and Phase 3 ZILRETTA timing.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning PCRX (Pacira BioSciences, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent PCRX coverage spans financial news, mergers & acquisitions and earnings.
The new distribution deal opens European markets for EXPAREL, potentially increasing sales and visibility.
The acquisitions modestly increase revenue base and signal continued roll‑up strategy, while the larger credit facility provides capacity for further deals.
Near-term trading focus is EXPAREL commercial momentum from expanded payer coverage plus execution on pipeline readouts (PCRX-201 Part A top-line later this year, ZILRETTA Phase 3 later this year).
Near-term sentiment should skew positive on revenue/earnings prints and the closed iovera transaction, but investors may focus on adjusted EBITDA softness and the post-divestiture earnings mix.
Separate reimbursement expansion with a major payer should support broader EXPAREL utilization and reduce adoption friction.
AlphAI scores every news story that mentions PCRX with an AI model for sentiment and relevance, and aggregates insider trades from Pacira BioSciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pacira BioSciences (PCRX) partnered with Molteni Farmaceutici to expand sales of its pain relief drug EXPAREL in the EU and U.K. The deal includes an upfront payment, supply price, and future royalties for Pacira. Financial details were not disclosed. The agreement aims to increase EXPAREL's market reach.
1 min readPharmaCorp Rx Inc. (PCRX) completed two acquisitions: a $1.3M pharmacy and a $475K prescription file purchase, expanding its network to 17 pharmacies. The company also increased its acquisition facility with CIBC from $17.5M to $27.5M. Additionally, it signed a non-binding LOI for three more pharmacies in Atlantic Canada.
1 min readPacira (PCRX) discussed its Q2 2026 earnings call, focusing on EXPAREL commercial momentum and pipeline progress. It said it secured UnitedHealthcare coverage for separate reimbursement, reaching 150 million covered lives by midyear toward a 160 million goal. Pacira also reported iovera divestiture completion to Zimmer Biomet on July 31 and outlined Phase 2 PCRX-201 Part B enrollment and Phase 3 ZILRETTA timing.
7 min readPacira BioSciences, Inc. (PCRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Second Quarter 2026 Financial Results -- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing pipeline, and high-caliber commercial partnerships -- -- Delivered second quart
6 min readPacira BioSciences (NASDAQ: PCRX) said UnitedHealthcare will provide separate reimbursement for EXPAREL (bupivacaine liposome injectable suspension) in outpatient settings, including hospital outpatient departments and ambulatory surgery centers. Pacira said this allows reimbursement outside surgical bundles for eligible members and expands access across ~40 million covered lives.
4 min readPacira BioSciences (PCRX) said it will sell its iovera business to Zimmer Biomet (ZBH) for up to $140M. The deal includes a $70M upfront payment and up to $70M in milestone payments through Dec. 31, 2031, with collaboration on a spasticity program. Closing is expected in Q3 2026; Pacira plans to use net proceeds to strengthen its balance sheet. PCRX rose premarket; ZBH fell.
4 min readPacira BioSciences, Inc. (PCRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. pcrx-20260628 6/28/2026 0001396814 false 0001396814 2026-06-28 2026-06-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event
2 min readPacira BioSciences, Inc. (PCRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 pacira2014amendedandrestat.htm EX-10.1 Document Exhibit 10.1 PACIRA BIOSCIENCES, INC. AMENDED AND RESTATED 2014 EMPLOYEE STOCK PURCHASE PLAN (As approved by stockholders on June 9, 2026) SECTION 1. PURPOSE The purposes of the Amended and Restated 2014 Employee Stock Pur
2 min readWILLIAMS KRISTEN (Chief Administrative Officer) sold 10,259 shares of Pacira BioSciences, Inc. (PCRX) at $22.27 ($0.23M total) on 2026-06-04 under a Rule 10b5-1 trading plan.
1 min readPacira BioSciences urged shareholders to vote the BLUE proxy card “FOR” its three director nominees ahead of its June 9, 2026 annual meeting. The company said proxy advisers ISS, Glass Lewis and Egan-Jones recommend “FOR” Pacira’s nominees and “AGAINST” DOMA Perpetual’s nominees. Pacira cited 2025 record revenue and Q1 2026 EXPAREL revenue of $143.3M (+5% YoY), ZILRETTA $26.8M (+15%) and iovera° $6.2M (+21%).
4 min read
